SSRIs not cause of birth defects
No significant association between use of selective serotonin-reuptake inhibitors in early pregnancy and congenital heart defects or most other birth defects was detected in a pair of case-control surveillance studies published in the June 28 issue of the New England Journal of Medicine. Results from the Slone Epidemiology Center Birth Defects Study found no significant increases in certain birth defects for the antidepressant class, but the findings "suggest that individual SSRIs may confer increased risks for some specific defects," although "the absolute risks are small." The Slone study found an association between sertraline (Pfizer's Zoloft and generics) and omphalocele and septal defects and between paroxetine (GlaxoSmithKline's Paxil and generics) and right ventricular outflow obstruction defects. Language regarding congenital malformations was added to Paxil labeling in 2005, and GSK is conducting its own epidemiologic studies examining the potential for birth defects (1"The Pink Sheet" Oct. 3, 2005, p. 10)...
You may also be interested in...
GlaxoSmithKline is conducting additional epidemiologic studies to better understand preliminary data suggesting a potential link between paroxetine use and birth defects, the company said in a "Dear Doctor" letter on revised labeling for Paxil CR and Paxil
Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.
Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.